Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors

Approximately 10% of unselected non-small-cell lung cancer (NSCLC) patients responded to the epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. However, resistance mechanisms are not well understood. We evaluated several potential biological markers of intrinsic EGFR-...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2008-09, Vol.19 (9), p.1605-1612
Hauptverfasser:	Zucali, P.A., Ruiz, M.G., Giovannetti, E., Destro, A., Varella-Garcia, M., Floor, K., Ceresoli, G.L., Rodriguez, J.A., Garassino, I., Comoglio, P., Roncalli, M., Santoro, A., Giaccone, G.
Format:	Artikel
Sprache:	eng
Schlagworte:	activated cMET Aged Antineoplastic agents Biological and medical sciences Biopsy, Needle Blotting, Western Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Cohort Studies Drug Resistance, Neoplasm Drug Screening Assays, Antitumor ErbB Receptors - antagonists & inhibitors Female Gefitinib gefitinib resistance Gene Expression Regulation, Neoplastic - drug effects Humans Immunohistochemistry In Situ Hybridization, Fluorescence Kaplan-Meier Estimate Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - mortality Male Medical sciences Middle Aged multitarget therapy Multivariate Analysis Mutation - drug effects Neoplasm Staging NSCLC Pharmacology. Drug treatments Pneumology Probability Proportional Hazards Models Protein Kinase Inhibitors - administration & dosage Protein-Tyrosine Kinases - drug effects Protein-Tyrosine Kinases - genetics Quinazolines - administration & dosage Survival Analysis Treatment Outcome Tumors of the respiratory system and mediastinum
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!